Biogen upgrade points to pipeline trial catalysts and share upside

Traders Union
All News
Financial News
Biogen upgrade and pipeline outlook

Highlights

JPMorgan upgraded Biogen to overweight with a $300 price target, implying 33% upside, citing multiple pipeline milestones in the next few quarters.
Biogen's felzartamab phase 3 data is expected in first half of 2027 and is seen as the largest pipeline opportunity, with potential to outperform current Street estimates.
Biogen shares are up around 28% year to date and 26 of 38 analysts have a buy or strong buy rating, according to LSEG data.

Upcoming trial data drive rating change

As reported by CNBC, citing JPMorgan, the investment bank sees an increasingly attractive catalyst path for Biogen as multiple pipeline programs approach important data releases over the next few quarters. Analyst Chris Schott says the stronger outlook supports both the rating upgrade from neutral to overweight and a higher valuation target, with the new $300 price objective implying 33% upside from Friday's close.

Schott highlights several expected milestones in 2027, including updates tied to felzartamab, readthroughs from Eli Lilly's TRAILBLAZER-ALZ-3 study relevant to Leqembi, and progress for litifilimab in cutaneous lupus erythematosus, or CLE. He says litifilimab stands out because there are currently no approved therapies for CLE, while data from two phase 3 trials testing the drug's efficacy is due in the fourth quarter of 2026.

JPMorgan also identifies felzartamab, an investigational treatment for rare kidney diseases, as the biggest opportunity in Biogen's pipeline. Phase 3 data for that treatment is expected in the first half of 2027, and Schott says the drug could outperform existing Street estimates based on its initial indication and its commercial potential if approved.

Sales outlook and market backing

Schott adds that felzartamab could ramp up sales quickly if it wins approval, pointing to what he describes as a relatively straightforward patient identification process for transplant patients and Biogen's experienced nephrology sales force following its Apellis acquisition. That commercial setup, combined with the upcoming clinical readout, underpins JPMorgan's view that the program can materially lift sentiment toward the stock.

The bank's stance broadly aligns with Wall Street consensus. LSEG data shows 26 of the 38 analysts covering Biogen hold a buy or strong buy rating on the shares, which are already up about 28% year to date.

UTI Asset Management’s credit rating reaffirmation was previously covered in our publication, highlighting how the decision reflected confidence in the firm’s operational framework and financial management amid intense competition in India’s asset management sector. We also noted that such rating actions can support credibility with investors and lenders, shaping market access, borrowing conditions, and overall confidence in the company’s longer-term stability.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.